Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data mart
These findings highlight the complexity of immune toxicities in early-phase trials, emphasizing the importance of the CIT class, as well as the roles of tumor burden, metastasis sites, and systemic immune state in the development of irAEs. Additionally, the observed association between skin toxicities and improved PFS suggests that skin toxicity could serve as a marker of systemic immune activation across immunotherapy contexts.
Authors
- Sarah Mycroft
- Vaios Karanikas (ORCID: https://orcid.org/0009-0009-9523-7425)
- Rajat Mohindra (ORCID: https://orcid.org/0009-0000-4233-5210)
- Guillemette Duchâteau-Nguyen (ORCID: https://orcid.org/0009-0002-3602-8104)
- Dominik Heinzmann (ORCID: https://orcid.org/0009-0001-7705-2816)
- Denis Lamparter
- Andreas Roller (ORCID: https://orcid.org/0000-0001-6335-0962)
- Nicolas Städler (ORCID: https://orcid.org/0000-0001-8212-7459)
- Cameron Adams (ORCID: https://orcid.org/0000-0003-2525-523X)
- Benjamin P. Fairfax (ORCID: https://orcid.org/0000-0001-7413-5002)
- Petar Šćepanović (ORCID: https://orcid.org/0000-0002-4686-7422)
- Tony Kam‐Thong (ORCID: https://orcid.org/0000-0002-5300-9573)
- Virginia Schmid
Institutions
- Roche (Switzerland) (CH)
- University of Oxford (GB)
- Roche (United Kingdom) (GB)
- Institute of Human Genetics (PL)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1136/jitc-2025-012891
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Genentech